Bayer Full-Year Report 2022

Sales at Crop Science advanced by 15.6% (Fx & portfolio adj.) to €25,169 million, with business up in all regions. We registered double-digit percentage gains in Latin America and Europe/Middle East/Africa, and also posted significant growth in North America and Asia/Pacific. Sales at Pharmaceuticals rose by 1.1% (Fx & portfolio adj.) to €19,252 million.

Economic Position and Target Attainment 2022 was a very successful year operationally. We registered a substantial increase in sales, with growth of 8.7% on a currency- and portfolio-adjusted basis (Fx & portfolio adj.). EBITDA before special items advanced by 20.9%, with the good business performance in the divisions more than offsetting inflation-driven cost increases. The EBITDA margin before special items amounted to 26.6%. At Crop Science, sales advanced by a double-digit percentage after adjusting for currency and portfolio effects, while EBITDA before special items rose by 46.2%, thanks in part to contributions from ongoing efficiency programs. Sales at Pharmaceuticals edged higher by 1.1% (Fx & portfolio adj.), and EBITDA before special items rose by 1.6%. Consumer Health registered encouraging sales growth of 8.4% on a currency- and portfolio-adjusted basis and a corresponding increase in EBITDA before special items, which advanced by 14.9%. Group earnings per share (total) came in at €4.22 in 2022, and were mainly weighed down by impairment losses. Core earnings per share rose by a substantial 22.0% to €7.94